FUT3 facilitates glucose metabolism of lung adenocarcinoma via activation of NF-κB pathway.
FUT3
Glucose metabolism
Lung adenocarcinoma
NF-κB pathway
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
13
05
2023
accepted:
28
09
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
Fucosyltransferases (FUTs) molecules have been identified to be involved in carcinogenesis of malignant tumors. Nevertheless, the biological function of fucosyltransferases-3 (FUT3) in lung adenocarcinoma (LUAD) malignant phenotype remains unclear. Herein, we investigated the association between FUT3 and LUAD pathological process. Immunochemistry, RT-qPCR and western blot assays were conducted to evaluate the expression of FUT3 in LUAD and corresponding adjacent tissues. The prognostic value of FUT3 was assessed via Kaplan‑Meier plotter database. The biological process and potential mechanism of FUT3 in LUAD were conducted via GSEA. Additionally, immunofluorescence and metabolite activity detection were performed to determine the potential role of FUT3 in LUAD glucose metabolism. The active biomarkers associated with NF-κB signaling pathway were detected via western blot. Subcutaneous tumor model was conducted to analyze the effect of FUT3 on tumorigenesis of LUAD. FUT3 was remarkably upregulated in LUAD tissues compared with adjacent tissues from individuals. FUT3 overexpression may predict poor prognosis of LUAD patients. Knockdown of FUT3 significantly inhibited tumor proliferation, migration and glucometabolic alteration in LUAD cells. Moreover, GSEA demonstrated that elevated FUT3 was positively related to NF-κB signaling pathway. Additionally, in vitro and in vivo assays also indicated that downregulation of FUT3 resulted in the suppression of oncogenesis and glucose metabolism via inactivation of NF-κB pathway. Our findings demonstrated that FUT3 was involved in glucometabolic process and tumorigenesis of LUAD via NF-κB signaling pathway. FUT3 may be an optimal target for diagnosis and treatment of LUAD patients.
Identifiants
pubmed: 37946130
doi: 10.1186/s12890-023-02688-x
pii: 10.1186/s12890-023-02688-x
pmc: PMC10636925
doi:
Substances chimiques
Fucosyltransferases
EC 2.4.1.-
Glucose
IY9XDZ35W2
NF-kappa B
0
3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase
EC 2.4.1.65
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
436Subventions
Organisme : Quanzhou High Level Talent Project
ID : 2020C001R
Organisme : Fujian Respiratory Medicine Center Talent Training Project
ID : HXZX202201
Informations de copyright
© 2023. The Author(s).
Références
Trends Genet. 2022 Jul;38(7):676-707
pubmed: 35504755
Glycobiology. 2011 Mar;21(3):387-96
pubmed: 20978012
Biochim Biophys Acta. 2011 Dec;1810(12):1141-9
pubmed: 21978830
Cochrane Database Syst Rev. 2021 Dec 6;12:CD011300
pubmed: 34870327
Semin Cancer Biol. 2018 Aug;51:116-128
pubmed: 28919484
Cell Death Dis. 2021 Jan 12;12(1):74
pubmed: 33436563
Mol Cancer. 2021 Feb 5;20(1):28
pubmed: 33546704
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188705
pubmed: 35276232
Trends Immunol. 2022 Sep;43(9):757-775
pubmed: 35965153
Biomolecules. 2022 Apr 14;12(4):
pubmed: 35454171
Cell Death Dis. 2021 Dec 2;12(12):1124
pubmed: 34857735
Semin Cancer Biol. 2017 Jun;44:141-152
pubmed: 28315783
Proteomics. 2008 Aug;8(16):3257-62
pubmed: 18646007
Gene. 2016 Mar 10;578(2):232-41
pubmed: 26701615
Genetica. 2003 Jul;118(2-3):157-70
pubmed: 12868606
Hepatology. 1998 Oct;28(4):944-52
pubmed: 9755230
Cell Mol Life Sci. 2016 Jan;73(2):377-92
pubmed: 26499846
Br J Cancer. 2020 May;122(11):1661-1672
pubmed: 32203219
Ther Adv Med Oncol. 2020 Jul 3;12:1758835920937902
pubmed: 32670423
Mol Med Rep. 2013 Apr;7(4):1336-42
pubmed: 23404530
Curr Oncol Rep. 2019 Feb 26;21(3):21
pubmed: 30806814
Nutr Diabetes. 2022 Apr 20;12(1):23
pubmed: 35443706
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
FASEB J. 2015 Aug;29(8):3217-27
pubmed: 25873065
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Oncol Lett. 2018 Jul;16(1):924-930
pubmed: 29963165
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Mol Carcinog. 2000 Apr;27(4):280-8
pubmed: 10747292
Glycobiology. 2020 Dec 9;30(12):941-969
pubmed: 32363402
Mediators Inflamm. 2019 Feb 19;2019:1082497
pubmed: 30906223
Br J Cancer. 2014 Jan 7;110(1):156-63
pubmed: 24253505
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11332-7
pubmed: 21709263
Ann Med. 2021 Dec;53(1):916-928
pubmed: 34134578
Cell Death Dis. 2013 Jul 25;4:e735
pubmed: 23887626
Int J Biochem Cell Biol. 2018 Jan;94:79-88
pubmed: 29208566
Gene. 2020 Feb 5;726:144158
pubmed: 31629815
Protein Cell. 2022 Dec;13(12):877-919
pubmed: 34050894
Cancer Sci. 2009 May;100(5):888-95
pubmed: 19302290
Cytokine. 2015 Sep;75(1):197-206
pubmed: 25934648